Pressure BioSciences (OTCQB: PBIO) today announced appointment of its Sr. Vice President and Chief Commercial Officer Dr. Bradford A. Young, effective Monday, November 5, 2018. In this new key position, Dr. Young’s responsibilities will include assessing multiple major opportunities in new and divergent markets, as well as optimizing strategy and commercialization priorities for the company. In addition to strategic planning, Dr. Young will build customer adoption and accelerate revenue growth through driving the execution of critical partnering and commercialization programs.
Young stated in the news release, “I am excited to join Pressure BioSciences at a time when I can help to develop and then lead commercial strategies to expand the utility and market penetration of our patented, pressure-based technology platforms, through customer-focused efforts to drive adoption and sales expansion. It is highly motivating to join a company driven by such cutting-edge scientific innovations, already spanning multiple major application areas, and supported by a diverse array of products and services to multiple customer segments.”
To view the full press release, visit http://ibn.fm/9594j
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.